Call Now Open
2026 Oxford-Harrington Rare Disease Scholar Award
January 15, 2026
The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking highly innovative projects for its 2026 Rare Disease Scholar Award, which accelerates promising therapeutics discoveries from academic labs...
Continue Reading
February 06, 2026
Harrington Discovery Institute at University Hospitals is supporting the development of a new drug called Zalunfiban that helped thousands of heart attack patients avoid complications in clinical trials. Continue Reading
January 29, 2026
Oxford-Harrington Rare Disease Centre operates a transatlantic model that embeds industry expertise directly into academic rare disease programs. $250 Million Committed to Advance 40 Therapies into Clinical Trials by 2034 Continue Reading
December 23, 2025
A conversation with Matthew P. Anderson, MD, Ph.D., co-director, Oxford-Harrington Rare Disease Centre, featured in Drug Discovery Online Continue Reading
November 14, 2025
Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and other devastating autoimmune diseases — by reprogramming patients’ out-of-whack immune systems. Continue Reading
July 20, 2025
Published in Good News NetworkEleven years of cancer research has proven fruitful for a scientist at Johns Hopkins who uncovered a new tumor-suppressive response that could lead to novel therapies targeting hard-to-treat cancers.The new study, funded in part by the National Institutes of Health and the National Cancer... Continue Reading
July 09, 2025
Experimental Compound Offers Potential Treatment for Rare, Often Fatal, Childhood Disease Continue Reading
July 09, 2025
Published in NatureAbstractDecreased brain levels of coenzyme Q10 (CoQ10), an endogenously synthesized lipophilic antioxidant,, underpin encephalopathy in primary CoQ10 deficiencies, and are associated with common neurodegenerative diseases and the ageing process,. CoQ10 supplementation does not increase CoQ10 pools in the... Continue Reading
June 19, 2025
Published in Cell Chemical BiologySignificanceEnzymes that regulate oncogenic protein function through the addition of post-translational modifications (PTMs) represent promising targets for the development of cancer therapeutics. N-glycosylation is a critical PTM that occurs in the lumen of the endoplasmic reticulum (ER) and... Continue Reading
June 04, 2025
The former prime minister has called for children admitted to paediatric care to undergo genome sequencing as part of a drive to cure 40 rare diseases Continue Reading
May 21, 2025
Alzheimer’s disease (AD) and traumatic brain injury (TBI) are currently untreatable neurodegenerative disorders afflicting millions of people worldwide. These conditions are pathologically related, and TBI is one of the greatest risk factors for AD. Continue Reading